2. Metabolic Enzyme/Protease
  3. FXR Factor Xa
  4. Licraside

Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC50 of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases.

For research use only. We do not sell to patients.

Licraside

Licraside Chemical Structure

CAS No. : 29913-71-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Licraside Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC50 of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases[1][2].

In Vitro

Licraside (20-800 μM; 24-72 h) shows ；low hepatotoxicity profile in HepG2 cells[1].
Licraside (20-100 μM; 24 h) acts as a dose-dependent FXR agonist in transiently transfected HepG2 cells, increasing BSEP promoter-driven luciferase activity[1].
Licraside (40-80 μM; 24 h) activates FXR signaling in HepG2 cells, significantly upregulating downstream SHP protein expression and BSEP protein expression[1].
Licraside inhibits factor Xa with an IC50 of 48.54 mM[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Licraside Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: HepG2 cells
Concentration: 20, 40, 80, 100, 800 μM
Incubation Time: 24 h; 72 h
Result: Did not reduce HepG2 cell viability after 24 h incubation at concentrations up to 800 μM.
Caused only a slight, non-significant decrease in cell viability at 20, 40, and 80 μM after 72 h incubation compared to 24 h treatment.
Caused significant hepatic cell death at 100 μM after 72 h incubation.

Western Blot Analysis[1]

Cell Line: HepG2 cells
Concentration: 40, 80 μM
Incubation Time: 24 h
Result: Significantly increased SHP protein expression compared to the control group at both 40 μM and 80 μM.
Significantly upregulated BSEP protein expression at 80 μM.
Caused non-statistically significant increases in BSEP expression at 40 μM.
In Vivo

Licraside (1-10 mg/kg; i.p.; daily; 7 days) effectively relieves ANIT (HY-W540630)-induced cholestasis in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 J (male, 8-10 weeks old, 18-20 g, ANIT-induced cholestasis)[1]
Dosage: 1 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.p.; daily; 7 days
Result: Significantly reduced biliary total bile acid (TBA) levels.
Significantly reduced serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), and TBA compared to the ANIT model group at medium and high doses.
Reduced fat vacuole formation and eliminated bile duct area inflammatory cell infiltration at low dose.
Resulted in clear liver cell nuclei, minimal hepatocyte necrosis, and no fat vacuole formation at medium dose.
Produced hepatocytes uniform in size, morphology, and structure, arranged neatly in radial patterns similar to the control group at high dose.
Caused slightly less weight loss than the ANIT group.
Molecular Weight

550.51

Formula

C26H30O13
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

OC1=C(C(/C=C/C2=CC=C(O)C=C2)=O)C=CC(O[C@H](O[C@H](CO)[C@@H](O)[C@@H]3O)[C@]3([H])O[C@H]4[C@@H]([C@](CO)(O)CO4)O)=C1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (181.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8165 mL 9.0825 mL 18.1650 mL
5 mM 0.3633 mL 1.8165 mL 3.6330 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1 mg/mL (1.82 mM); Clear solution

    This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 1 mg/mL (1.82 mM); Clear solution

    This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.95%

SDS (252 KB)

COA (250 KB) HNMR (321 KB) RP-HPLC (244 KB) MS (229 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.8165 mL 9.0825 mL 18.1650 mL 45.4124 mL
5 mM 0.3633 mL 1.8165 mL 3.6330 mL 9.0825 mL
10 mM 0.1816 mL 0.9082 mL 1.8165 mL 4.5412 mL
15 mM 0.1211 mL 0.6055 mL 1.2110 mL 3.0275 mL
20 mM 0.0908 mL 0.4541 mL 0.9082 mL 2.2706 mL
25 mM 0.0727 mL 0.3633 mL 0.7266 mL 1.8165 mL
30 mM 0.0605 mL 0.3027 mL 0.6055 mL 1.5137 mL
40 mM 0.0454 mL 0.2271 mL 0.4541 mL 1.1353 mL
50 mM 0.0363 mL 0.1816 mL 0.3633 mL 0.9082 mL
60 mM 0.0303 mL 0.1514 mL 0.3027 mL 0.7569 mL
80 mM 0.0227 mL 0.1135 mL 0.2271 mL 0.5677 mL
100 mM 0.0182 mL 0.0908 mL 0.1816 mL 0.4541 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Licraside Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Licraside29913-71-1FXRFactor XaNR1H4FxaHERG K+ channelSHPBSEPcholestasisHepG2 cellsmiceANIT-induced cholestasisthromboembolic diseasesFarnesoid X receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Licraside
Cat. No.:
HY-N6987
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.